Skip to main content
SpringerLink
Log in

Treatment recommendations for the various subgroups of neurocytomas

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Neurocytomas gained importance since 1995, which is reflected by the increasing number of reports on this entity. This study was performed to determine the best available treatment for typical and atypical neurocytomas (MIB-1 labeling index >‰3%, atypical histology) in various age groups (‰≤‰18 years, >‰18 years).

The data of all neurocytoma patients reported since 1982, when this entity were reviewed for age, gender, extent of resection, MIB-1 labeling index, histology, radiotherapy, and outcome of therapy. Patients were treated with complete resection alone (CTR), CTR plus radiotherapy (CTR + RT), incomplete resection alone (ITR), or ITR plus radiotherapy (ITR + RT). If the reported data were incomplete, the authors were contacted for additional data. Follow up had to be at least 12 months.

Data were complete in 438 patients (73 children, 365 adults). Three hundred and fifty-one patients had typical, 87 atypical lesions. Typical lesions were associated with better local control and survival than atypical lesions (P < 0.001). CTR was superior to ITR (P < 0.001). After CTR, outcome was not significantly improved by RT. After ITR, RT improved survival in typical lesions (P = 0.03) and atypical lesions (P = 0.05), not in children (P = 0.16). Local control was improved in all groups (P < 0.001, children P = 0.01). Doses >‰54 Gy appeared beneficial after ITR of atypical lesions. In children, ≤50 Gy and >50 Gy were comparable.

CTR does not require post-operative RT. Following ITR, RT improves outcome. Of 50–54 Gy appear sufficient for typical lesions, 50 Gy for children. Atypical lesions require 56–60 Gy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rades D, Fehlauer F, Lamszus K, et al. 2005 Well-differentiated neurocytoma: what is the best available treatment? Neuro-Oncol 7: 77–83

    Article  PubMed  Google Scholar 

  2. Ashkan K, Casey ATH, D’Arrigo C, Harkness WF, Thomas DGT, 2000 Benign central neurocytoma. A double misnomer? Cancer 89: 1111–1120

    Article  PubMed  CAS  Google Scholar 

  3. Rades D, Fehlauer F, Schild SE, 2004 Treatment of atypical neurocytomas Cancer 100: 814–817

    Article  PubMed  Google Scholar 

  4. Rades D, Fehlauer F, Schild SE, 2004 The prognostic value of the MIB-1 labeling index for central neurocytomas Neurology 62: 987–989

    PubMed  Google Scholar 

  5. Hassoun J, Soylemezoglu F, Gamberelli D, Figarella-Branger D, von Ammon K, Kleihues P, 1993 Central neurocytoma: a synopsis of clinical and histological features Brain Pathol 3: 297–306

    PubMed  CAS  Google Scholar 

  6. Salvati M, Cervoni L, Caruso R, Gagliardi FM, 1997 Central neurocytoma: clinical features of 8 cases Neurosurg Rev 20: 39–43

    Article  PubMed  CAS  Google Scholar 

  7. Stephan CL, Kepes JJ, Arnold P, Green KD, Chamberlin F, 1999 Neurocytoma of the cauda equina. Case report J Neurosurg 90: 247–251

    PubMed  CAS  Google Scholar 

  8. Tatter SB, Borges LF, Louis DN, 1994 Central neurocytomas of the cervical spinal cord. Report of two cases J Neurosurg 81: 288–293

    PubMed  CAS  Google Scholar 

  9. Favereaux A, Vital A, Loiseau H, Dousset V, Caille J, Petry K, 2000 Histopathological variants of central neurocytoma: report of 10 cases Ann Pathol 20: 558–563

    PubMed  CAS  Google Scholar 

  10. Uematsu Y, Tanakla Y, Shimizu M, et al. 2001 Histogenesis and proliferative activity of central neurocytomas Brain Tumor Pathol 18: 29–36

    Article  PubMed  CAS  Google Scholar 

  11. Ishiuchi S, Tamura M, 1997 Central neurocytoma: an immunohistochemical, ultrastructural and cell culture study Acta Neuropathol 94: 425–435

    Article  PubMed  CAS  Google Scholar 

  12. Soylemezoglu F, Onder S, Tezel GG, Berker M, 2003 Neuronal nuclear antigen (NeuN): a new tool in the diagnosis of central neurocytoma Pathol Res Pract 199: 463–468

    Article  PubMed  CAS  Google Scholar 

  13. Chang KH, Han MH, Kim DG, et al. 1993 MR appearance of central neurocytoma Acta Radiol 34: 520–526

    Article  PubMed  CAS  Google Scholar 

  14. Sgouros S, Carey M, Aluwihare N, Barber P, Jackowski A, 1998 Central neurocytoma: a correlative clinicopathologic and radiologic analysis Surg Neurol 49: 197–204

    Article  PubMed  CAS  Google Scholar 

  15. Jamshidi J, Izumoto S, Yoshimine T, Maruno M, 2001 Central neurocytoma presenting with intratumoral hemorrhage Neurosurg Rev 24: 48–52

    Article  PubMed  CAS  Google Scholar 

  16. Tomura N, Hirano H, Watanabe O, et al. 1997 Central neurocytoma with clinically malignant behavior Am J Neuroradiol 18: 1175–1178

    PubMed  CAS  Google Scholar 

  17. Hassoun J, Gambarelli D, Grisoli F, et al. 1982 Central neurocytoma. An electron-microscopic study of two cases Acta Neuropathol 56: 151–156

    Article  PubMed  CAS  Google Scholar 

  18. Rades D, Schild SE, Fehlauer F, 2004 Defining the best available treatment for neurocytomas in children Cancer 101: 2629–2632

    Article  PubMed  Google Scholar 

  19. Brat DJ, Scheithauer BW, Eberhart CG, Burger PC, 2001 Extraventricular neurocytomas: pathologic features and clinical outcome Am J Surg Pathol 25: 1252–1260

    Article  PubMed  CAS  Google Scholar 

  20. Eng DY, DeMonte F, Ginsberg L, Fuller GN, Jaeckle K, 1997 Craniospinal dissemination of central neurocytoma. Report of two cases J Neurosurg 86: 547–552

    Article  PubMed  CAS  Google Scholar 

  21. Tacconi L, Rossi M, Foy P, 2000 Central neurocytoma: long-term follow-up in a pediatric case J Clin Neurosci 7: 542–560

    Article  Google Scholar 

  22. Relling MV, Rubnitz JE, Rivera GK, et al. 1999 High incidence of secondary brain tumours after radiotherapy and antimetabolites Lancet 354: 34–39

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

    Dirk Rades

  2. Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA

    Steven E. Schild

  3. Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246, Hamburg, Germany

    Dirk Rades

Authors
  1. Dirk Rades
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven E. Schild
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Rades.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rades, D., Schild, S.E. Treatment recommendations for the various subgroups of neurocytomas. J Neurooncol 77, 305–309 (2006). https://doi.org/10.1007/s11060-005-9047-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-9047-3

Keywords

Search

Navigation